Department of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, Hufelandstraße 55, 45147, Essen, Germany.
Department for Radiotherapy, University Hospital Essen, Hufelandstraße 55, 45147, Essen, Germany.
Mol Imaging Biol. 2020 Jun;22(3):788-796. doi: 10.1007/s11307-019-01424-4.
The aim of this study was to evaluate the detection rate of [Ga]prostate-specific membrane antigen ([Ga]PSMA-11) positron emission tomography (PET)/magnetic resonance imaging (MRI) and to compare it with [Ga]PSMA-11 PET/X-ray computed tomography (CT) in patients with recurrent prostate cancer (PC) after radical prostatectomy.
A total of 93 patients with biochemically recurrent prostate cancer underwent [Ga]PSMA-11 PET/CT and subsequently a whole-body integrated PET/MRI examination. Board certified nuclear medicine physicians and radiologists evaluated PET/CT and PET/MRI datasets regarding identification of tumor lesions ((i) lymph nodes, (ii) bone lesions, (iii) local recurrence, and (iv) parenchymal lesions) based on maximum [Ga]PSMA-11 uptake as well as morphological changes. Quality of PET images for both PET/CT and PET/MRI were rated using a 5-point scoring system by evaluating lesion homogeneity, contrast, contour, and delineation. Wilcoxon signed-rank tests were used to determine statistical differences.
PC relapse was detected in 62/93 patients. PET/MRI detected 148 out of 150 lesions described in PET/CT. In addition, PET/MRI detected 11 lesions not detected in PET/CT (5 lymph nodes, 6 local recurrences). The exact McNemar statistical test (one-sided) showed significant difference between PET/CT and PET/MRI for diagnosis of local recurrence (p value = 0.031). Diagnostic confidence for (iii) was higher in PET/MRI compared with PET/CT (PET/CT = 1.1; PET/MRI = 4.9). Diagnostic confidence for (i) (PET/CT = 4.9; PET/MRI = 4.6), (ii) (PET/CT = 4.9; PET/MRI = 4.6), and (iv) (PET/CT = 4.6; PET/MRI = 4.8) was equivalent between PET/MRI and PET/CT.
Integrated [Ga]PSMA-11 PET/MRI provides a similarly high diagnostic performance for localization of recurrent PC as PET/CT. For the detection of local recurrences [Ga]PSMA-11 PET/MRI is superior compared with [Ga]PSMA-11 PET/CT.
本研究旨在评估[Ga]前列腺特异性膜抗原([Ga]PSMA-11)正电子发射断层扫描(PET)/磁共振成像(MRI)的检出率,并将其与[Ga]PSMA-11 PET/X射线计算机断层扫描(CT)在根治性前列腺切除术后复发性前列腺癌(PC)患者中的应用进行比较。
共 93 例生化复发的前列腺癌患者接受了[Ga]PSMA-11 PET/CT 检查,随后进行了全身整合的 PET/MRI 检查。核医学医师和放射科医师根据最大[Ga]PSMA-11摄取以及形态学变化,对 PET/CT 和 PET/MRI 数据集进行肿瘤病变((i)淋巴结,(ii)骨病变,(iii)局部复发,和(iv)实质病变)的识别。采用 5 分制评分系统对 PET/CT 和 PET/MRI 的 PET 图像质量进行评分,评估病变的均匀性、对比度、轮廓和勾画。采用 Wilcoxon 符号秩检验比较统计差异。
93 例患者中有 62 例检测到 PC 复发。PET/MRI 检测到 150 个在 PET/CT 中描述的病灶中的 148 个。此外,PET/MRI 还检测到 11 个在 PET/CT 中未检测到的病灶(5 个淋巴结,6 个局部复发)。确切的 McNemar 单侧统计检验(one-sided)显示,局部复发的诊断中 PET/CT 和 PET/MRI 之间存在显著差异(p 值=0.031)。与 PET/CT 相比,(iii)的诊断置信度在 PET/MRI 中更高(PET/CT=1.1;PET/MRI=4.9)。(i)(PET/CT=4.9;PET/MRI=4.6)、(ii)(PET/CT=4.9;PET/MRI=4.6)和(iv)(PET/CT=4.6;PET/MRI=4.8)的诊断置信度在 PET/MRI 和 PET/CT 之间相当。
整合的[Ga]PSMA-11 PET/MRI 对复发性 PC 的定位具有与 PET/CT 相似的高诊断性能。与[Ga]PSMA-11 PET/CT 相比,[Ga]PSMA-11 PET/MRI 更适合检测局部复发。